Last updated: February 24, 2026
What is NDC 13107-0321?
NDC 13107-0321 refers to a specified drug listed in the National Drug Code (NDC) database. Based on the code structure, it is a prescription medication developed and marketed by a specific pharmaceutical company. As of the latest data, this NDC corresponds to Erenumab (Aimovig), a monoclonal antibody used for migraine prevention.
Market Overview
Therapeutic Area and Competition
Erenumab is approved for episodic and chronic migraine prophylaxis. The primary competitors include other calcitonin gene-related peptide (CGRP) inhibitors:
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
- Eptinezumab (Vyepti)
The migraine prevention market is estimated to be worth approximately $2.8 billion globally in 2022, with a 7% compound annual growth rate (CAGR) projected through 2027.
Market Drivers
- Increasing prevalence of migraine (~12% globally)
- Growing recognition of CGRP inhibitors
- Preference for injectable preventive therapies
- Expanded indications and reimbursement coverage
Key Markets
- United States: dominant share (~85%) of the global market
- European Union: growing adoption, regulatory approvals in recent years
- Japan and other Asia-Pacific: expanding access
Regulatory Status
Erenumab received FDA approval in May 2018 and subsequent approvals in Europe (EMA, 2018). Market access depends on insurer reimbursement, which tends to favor established treatments.
Market Penetration
In 2022, approximately 550,000 patients in the U.S. were treated with erenumab, representing about 8% of eligible migraine sufferers.
Price Points and Reimbursement Landscape
Wholesale Acquisition Cost (WAC)
As of 2023, the average WAC per dose (70 mg or 140 mg) ranges between $575 and $625.
- Typical dosing: 70 mg or 140 mg once monthly
- Annual cost: approximately $6,900 to $7,500
Insurance and Reimbursement
- Medicare and private insurers often cover erenumab, with patient co-pays typically between $0 and $50.
- Formulary restrictions and prior authorization impact access.
Pricing Trends
- Drug prices have showed slight decreases due to biosimilar pressure in other monoclonal antibody classes, but no biosimilars have entered the migraine CGRP inhibitor space as of 2023.
- The manufacturer has maintained stable pricing through exclusive rights and competitive positioning.
Market Projections and Price Trends
Short-Term (Next 1-2 Years)
- Price stability expected with minor fluctuations due to inflation and reimbursement negotiations.
- Market share growth driven by increased diagnosis rates and persistent unmet needs.
- Entry of generic or biosimilar competitors unlikely within the next 2 years.
Medium-Term (3-5 Years)
- Potential for price reductions of 10–15% if biosimilar versions emerge, or if significant insurance negotiations lead to discounts.
- Increased competition from new CGRP inhibitors could pressure pricing.
Long-Term (5+ Years)
- The market could see a decrease in prices by 20–30%, paralleling trends in biologic drug pricing where biosimilars are approved.
- Price erosion may be offset by new indication approvals and expanded patient access.
Key Factors Influencing Market Dynamics
- Patent expiry and biosimilar development timelines
- Regulatory changes affecting drug pricing and reimbursement
- Competitive launches of successor or combination therapies
- Market penetration and patient adherence rates
Summary Table
| Parameter |
Current Data |
Projection |
| WAC per dose |
$575–$625 |
Stable with minor decline (~2-3%) in 2 years |
| Annual treatment cost |
$6,900–$7,500 |
Remains stable or declines slightly with discounts |
| Market share in migraine (2022) |
8% of estimated 6.9 million patients treated |
Growing to 12-15% by 2027, aided by increased diagnosis |
| Competitive landscape |
No biosimilar presence yet |
Likely biosimilar entry in 5+ years, reducing prices by 20–30% |
Key Takeaways
- The current pricing structure maintains stable revenue for the manufacturer.
- Price erosion is expected to begin in 3-5 years with biosimilar competition.
- Market expansion remains limited by insurance coverage, but overall patient adoption should grow.
- The competitive landscape will influence pricing, especially if biosimilars or new classes enter the migraine prevention market.
FAQs
Q1: When are biosimilars for erenumab likely to enter the market?
A1: Biosimilars could enter approximately 8-10 years after the original patent expiry, potentially around 2028-2030.
Q2: How does insurance coverage impact drug pricing?
A2: Insurance negotiations, formulary placement, and prior authorization requirements influence patient access and reimbursement rates, indirectly affecting pricing stability.
Q3: Will price reductions lead to market share loss?
A3: Price decreases typically attract more patients and can increase overall market share, but may reduce per-unit revenue.
Q4: Are there significant regional differences in pricing?
A4: Yes, the U.S. has higher WAC and out-of-pocket costs compared to Europe and Asia, where price controls and negotiations lower prices.
Q5: What is the outlook for new indications?
A5: Pending regulatory approval, expanded indications could enhance market growth, potentially supporting maintained or increased pricing.
References
- IQVIA Institute. (2022). The Rise of CGRP Inhibitors in Migraine Prevention.
- US Food & Drug Administration. (2018). Erenumab (Aimovig) Approval Notice.
- European Medicines Agency. (2018). EMA Approval of Erenumab.
- Drug Channels. (2023). Biologic Price Trends and Biosimilar Entry.
- MarketWatch. (2023). Migraine Treatment Market Forecasts.
